ArticleScientific reports2025
Versatile tethering system to control cell-specific targeting of bioengineered extracellular vesicles.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Ternary MOF-PEDOT: PSS/AuNPs nanocomposite for ultrasensitive electrochemical detection of extracellular vesicles.Mikrochimica acta · 2026Article
- Extracellular vesicles in solid tumors: from tumor ecology to engineered therapeutics.Molecular cancer · 2026Review
- Lactylation modification in extracellular vesicles: A key regulator of cellular communication.iScience · 2026Review
- Bioengineering of extracellular vesicles with scaffold proteins for drug delivery.Journal of nanobiotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular Vesicles (EVs) are natural communication vectors involved in many physiological processes. Significant efforts have aimed to harness EVs for therapeutic delivery, with key challenges being control and enhancement of EV-mediated delivery steps. We and others have developed strategies to improve cargo loading and enhance EV content delivery using viral or non-viral fusogens. However, few targeting solutions have been proposed. Here, we present a versatile system for precise EV targeting to specific cell types, enabling quantitative assessment of targeting efficiency via luminescence and fluorescence. EVs are genetically engineered to express a chimeric adapter protein anchored by a glycosylphosphatidylinositol (GPI) anchor. This protein includes a fluorescent/luminescent domain for detection and a streptavidin domain recruit biotinylated antibodies or ligands specific to cell-surface antigens or receptors. We validated this platform with three different combinations of ligand/target cells, demonstrating up to 40-fold increase in EV uptake. This adaptable system promises to provide a comprehensive solution for targeted therapeutic delivery using EV-based vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.